Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child.

Abstract

UNLABELLED:

A 13-year-old Japanese boy with pituitary prolactinoma whose growth had been retarded for more than 2 years was treated with bromocriptine alone for 140 weeks. After treatment, the serum level of prolactin, which was 1200 ng/ml before treatment, returned to normal and the pituitary tumour seen on the initial brain MRI had rapidly decreased in size after 16 weeks of treatment. Thereafter, his height improved (from -2.1 to -1.7 SDS).

CONCLUSION:

the favourable response obtained in this patient implies that bromocriptine monotherapy can be an effective first-line treatment for children with prolactinoma.

• Authors: Satoru Sakazume, Kazuo Obata, Etsurou Takahashi, Atsunori Yoshino, Nobuyuki Murakami, Ryoich Sakuta, Takayasu Murai, Toshiro Nagai
• Journal: European journal of pediatrics (Eur J Pediatr) Vol. 163 Issue 8 Pg. 472-4 (Aug 2004) ISSN: 0340-6199 [Print] Germany
• PMID: 15160292 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2004 Springer-Verlag

Chemical References

• Dopamine Agonists
• Bromocriptine

Topics

• Adolescent
• Bromocriptine (therapeutic use)
• Dopamine Agonists (therapeutic use)
• Growth Disorders (drug therapy, etiology)
• Humans
• Hyperprolactinemia (complications, drug therapy)
• Male
• Pituitary Neoplasms (complications, drug therapy)
• Prolactinoma (complications, drug therapy)